Brolucizumab for treating wet age-related macular degeneration

  • Technology appraisal guidance
  • TA672
  • Published: 
Download guidance (PDF)

2 Information about brolucizumab

Marketing authorisation indication

2.1 Brolucizumab (Beovu, Novartis) is indicated 'in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD)'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.

Price

2.3 The price of brolucizumab is £816.00 per 120 mg/ml solution for injection in a pre-filled syringe (excluding VAT; BNF). The company has a commercial arrangement. This makes brolucizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.